NCT06791083

Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer

Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer: a Single-arm, Open Clinical Study

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: First Affiliated Hospital of Fujian Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To observe and evaluate the neoadjuvant treatment of Envafolimab combined with Fruquintinib and chemotherapy for locally advanced gastric/gastroesophageal junction carcinoma

Detailed description

This study observed and evaluated the major pathological response rate (MPR), pathological complete response rate (pCR), pathological response rate (pRR), objective response rate (ORR), R0 removal rate, disease-free survival (DFS) of Envafolimab combined with Fruquintinib and chemotherapy in neoadjuvant therapy for locally advanced gastric/gastroesophageal junctional cancer. Overall survival (OS) and security. The relationship between tumor angiogenesis and lymphangiogenesis and clinical outcome of patients (including but not limited to immunohistochemical detection of CD31, CD3, CD8, etc.) was also explored.

Conditions

• Gastric Cancer

Interventions

Type	Name	Description
DRUG	Envafolimab	150mg/m2 , IH， d1；Q3W
DRUG	Fruquintinib	5 mg ，po，QD，d1-d14；Q3W

Timeline

• Start date: 2024-06-20
• Primary completion: 2025-12-01
• Completion: 2027-05-01
• First posted: 2025-01-24
• Last updated: 2025-01-24

Locations

1 site across 1 country: China